TCR2 Therapeutics Submits Matters to a Vote of Security Holders

Trending News ☀️

TCR2 ($NASDAQ:TCRR) Therapeutics Inc. is a clinical-stage immuno-oncology company developing novel T cell therapies for the treatment of cancer. The submission of matters to a vote of security holders by TCR2 Therapeutics Inc. is hereby authorized. This will allow the company to move forward with important decisions that need to be made in order to continue developing their life-saving therapies. Security holders can rest assured that their interests are being taken into consideration by the company’s leadership.

Stock Price

The media coverage surrounding the company has been mostly positive. However, on Monday, TCR2 THERAPEUTICS stock opened at $1.6 and closed at $1.6, down by 1.2% from prior closing price of 1.6. Live Quote…

About the Company

VI Analysis

TCR2 THERAPEUTICS is a medium risk investment in terms of financial and business aspects, according to the VI Risk Rating. The company’s fundamentals reflect its long term potential, but there are 4 risk warnings in the income sheet, balance sheet, cashflow statement, and financial journal. Register with us to check it out. More…

VI Peers

The company’s lead program is Tigatuzumab, which is in Phase II clinical trials for the treatment of solid tumors. TCR2 is also developing a pipeline of other T cell therapies with the potential to treat a range of cancers. TCR2’s main competitors are Brainstorm Cell Therapeutics Inc, Iovance Biotherapeutics Inc, and Immatics NV. These companies are also developing T cell therapies for the treatment of cancer.

– Brainstorm Cell Therapeutics Inc ($NASDAQ:BCLI)

Brainstorm Cell Therapeutics Inc is a biotechnology company that develops and commercializes adult stem cell therapies for neurodegenerative diseases. The company has a market cap of 59.84M and a ROE of -137.41%. Brainstorm Cell Therapeutics Inc was founded in 2004 and is headquartered in New York, New York.

– Iovance Biotherapeutics Inc ($NASDAQ:IOVA)

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of cancer immunotherapy products based on tumor-infiltrating lymphocytes (TIL). The company’s product candidates include LN-144, LN-145, LN-168, and LN-169. LN-144 is in Phase II clinical trials for the treatment of metastatic melanoma; LN-145 in Phase I/II clinical trials for the treatment of cervical, head and neck, and non-small cell lung cancers; LN-168 in Phase I/II clinical trials for the treatment of ovarian and gastric cancers; and LN-169 in Phase I/II clinical trials for the treatment of bladder cancer. Iovance Biotherapeutics was founded by Philip D. Gregory and Maria Fardis on October 3, 2011 and is headquartered in San Carlos, CA.

– Immatics NV ($NASDAQ:IMTX)

Immatics NV, a clinical-stage biopharmaceutical company, focuses on the development of T cell-based immunotherapies for the treatment of cancer. The company’s product candidates include IMA901 that is in Phase II clinical trials for the treatment of solid tumors, as well as in Phase I/II trials for the treatment of acute myeloid leukemia and multiple myeloma; IMA950, which is in Phase I clinical trial for the treatment of pancreatic cancer; and IMA960, a preclinical stage product candidate for the treatment of glioblastoma. Immatics NV was founded in 1999 and is headquartered in Martinsried, Germany.

Summary

TCR2 Therapeutics is a clinical-stage immuno-oncology company developing novel T cell therapies for the treatment of patients with cancer. Investing in TCR2 Therapeutics provides investors with exposure to a promising immuno-oncology company with a lead product candidate that has shown promise in preclinical studies. The company is currently enrolling patients in a Phase 1 clinical trial and is also developing a second product candidate.